Pharmacology, Toxicology and Pharmaceutical Science
Adult Onset Still Disease
5%
Adverse Drug Reaction
32%
Angiotensin Receptor Antagonist
12%
Biological Product
32%
C Reactive Protein
11%
Chronic Kidney Failure
100%
Combination Therapy
32%
Connective Tissue Disease
32%
Cotrimoxazole
32%
Creatinine
8%
Dapagliflozin
32%
Disease Activity
39%
Disease Exacerbation
53%
Disease Modifying Antirheumatic Drug
32%
Glucocorticoid
16%
Inflammation
8%
Lupus Erythematosus Nephritis
32%
Monotherapy
18%
Musculoskeletal Disease
97%
Peripheral Vasodilating Agent
32%
Prednisolone
8%
Pulmonary Hypertension
32%
Remission
37%
Rheumatic Disease
32%
Rheumatoid Arthritis
32%
Sarcopenia
32%
Systemic Lupus Erythematosus
32%
Tacrolimus
9%
Tocilizumab
7%
Vasodilator Agent
9%
Medicine and Dentistry
Adult Onset Still Disease
5%
Adverse Drug Reaction
32%
Anti-dsDNA Antibodies
10%
Biological Product
32%
Body Weight
9%
Bone Mass
12%
C Reactive Protein
7%
Chronic Kidney Disease
67%
Clinical Disease Activity Index
7%
Combination Therapy
32%
Connective Tissue Disease
32%
Creatinine
24%
Disease Activity
32%
Disease Duration
8%
Disease Exacerbation
53%
Disease Modifying Antirheumatic Drug
32%
Drug Megadose
16%
Glomerular Filtration Rate
6%
Glucocorticoid
16%
Lupus Erythematosus
32%
Lupus Nephritis
32%
Lymphocyte
5%
Mental Capacity
6%
Monotherapy
18%
Musculoskeletal Disease
64%
Peripheral Vasodilating Agent
32%
Prednisolone
8%
Pulmonary Hypertension
32%
Rheumatic Disease
32%
Rheumatoid Arthritis
32%
Sarcopenia
32%
Spontaneous Remission
5%
Systemic Lupus Erythematosus
32%
Systolic Blood Pressure
9%
Tocilizumab
7%
Trimethoprim/Sulfamethoxazole
32%
Vasodilator Agent
9%
Keyphrases
Abatacept
5%
Adult-onset Still's Disease
5%
Adverse Drug Reaction
32%
Angiotensin Receptor Blockers
12%
Best Response
9%
Biologic Disease-modifying Antirheumatic Drugs
32%
C-means
5%
C-reactive Protein Level
10%
Calgranulin B
8%
Chronic Kidney Disease
67%
Clinical Activity Score
10%
Consecutive Patients
8%
Dapagliflozin
32%
Decreased Risk
5%
Early Combination Therapy
5%
Estimated Glomerular Filtration Rate
5%
Estimated Glomerular Filtration Rate Slope
9%
Index Score
10%
Inflammation
5%
Kidney Disease Progression
32%
Lymphocyte Count
5%
Multivariable
5%
Musculoskeletal Disorders
32%
Renal Flare
32%
Renal Function
9%
Response Rate
9%
Rheumatic Diseases
32%
Rheumatic musculoskeletal Disease
64%
Rheumatoid Arthritis
32%
Rheumatoid Arthritis Patients
5%
Risk Factors
32%
SARS-CoV-2 mRNA Vaccination
32%
Tacrolimus
9%
Tocilizumab
10%
Trimethoprim-sulfamethoxazole (TMP-SMX)
32%
Tumour Necrosis Factor Inhibitor (TNFi)
5%
